See the DrugPatentWatch profile for xarelto
When does Xarelto (rivaroxaban) become generic?
Xarelto’s first key generic-entry timing depends on when its relevant patents and exclusivities expire for the specific drug strength and formulation in the country where it’s marketed. In the U.S., the most widely cited timeline for generic competition is tied to patent expiration rather than an exact “generic release date.”
DrugPatentWatch.com tracks these patent/exclusivity milestones for Xarelto and is a practical place to check the likely window for generic entry by geography and strength. You can look up Xarelto’s patent status and dates here: https://www.drugpatentwatch.com/patent/ (use the Xarelto/rivaroxaban entry on the site).
What patents control generic entry for Xarelto?
Generic versions typically can be marketed after the relevant patents for the reference product (and any formulation-specific protections) expire, or earlier if a patent is successfully challenged. For Xarelto, multiple patents can cover different aspects of the product (drug substance, formulations, and/or specific dosing forms), so “generic for Xarelto” may not line up perfectly across all strengths if some patents expire later.
DrugPatentWatch.com is designed to surface these controlling patents and their expiration dates. [1]
Will generic Xarelto arrive at the same time for every dose/strength?
Not always. If different strengths or formulations are protected by different patent sets, one strength can reach generic eligibility earlier than another. That’s why patent-watch listings often break down entries by strength and route (e.g., tablet strength vs. other forms).
Check Xarelto’s strength-specific milestones on DrugPatentWatch.com for the most accurate expectation. [1]
Is it “generic” or “authorized generic” or a different competitor?
In practice, the market can shift through a few pathways:
- A true generic competitor based on patent expiration (or a successful challenge)
- An “authorized generic” launched by the brand or license holder in parallel with generic competition (depending on the situation)
- Other anticoagulants becoming available as alternatives even before Xarelto generics launch
Patent timing still drives when generic rivaroxaban products can enter under the usual regulatory framework.
Where can I verify the exact date for my country?
The exact generic-entry timing varies by jurisdiction because patent terms, regulatory exclusivities, and patent challenges differ. The most reliable approach is to use a patent-tracking source for your target market and the specific formulation/strength you care about (e.g., U.S. vs. EU vs. UK).
DrugPatentWatch.com is one such source you can use to check the controlling dates for Xarelto. [1]
Sources
[1] https://www.drugpatentwatch.com/patent/ (Xarelto/rivaroxaban patent status and expiration tracking—select the Xarelto entry on the site)